The last time psychedelics were used for therapy in the Netherlands, was when Leiden University Professor of Psychiatry Jan Bastiaans was treating concentration camp survivors and their trauma with LSD- and psilocybin-assisted psychotherapy. Bastiaans treated about 300 patients, mostly with LSD, until his retirement in 1985. Now, after a long hiatus in psychedelic research in the Netherlands and elsewhere, several clinical studies into psychedelics-assisted psychotherapy are currently underway.
The largest research to date is now coming to three Dutch university medical centers – Groningen, Leiden and Utrecht – focusing on using psilocybin-assisted therapy for treatment-resistant depression.
This study, a phase IIb dose-ranging study with 216 patients financed by Compass Pathways, is carried out in a number of sites across North America and Europe, including the Netherlands at said universities. If successful, it will be followed by phase III studies, paving the way for the use of psilocybin-assisted therapy as a standard treatment against depression.
At the moment, these three research sites are recruiting subjects over the age of 18 who will receive either 1mg, 10 mg or 25 mg of psilocybin in a single session. Full details regarding study design and admission criteria can be found at their web pages (Groningen, Leiden, Utrecht).
ICPR 2020 is an interdisciplinary conference about the latest science in psychedelics research focusing on psychology, neuroscience, anthropology and psychiatry. It will be held on 24-26 April 2020 in Haarlem, the Netherlands. Look at the programme here.
Our accredited International Symposium on Psychedelics in Psychiatry and Psychotherapy, organised especially for healthcare professionals, will showcase the latest clinical evidence on psychedelics in the treatment of mental disorders. All of the speakers at the Symposium will also present their work at the ICPR 2020 conference.
In another study in the Netherlands, the Department of Psychology and Neuroscience at Maastricht University is testing the effects of a single administration of ‘a naturally occurring psychedelic substance’ on treatment-resistant depression. Previously, the same research team had tested the same compound on healthy volunteers, and the trial is now going into its clinical phase with subjects between 18 and 64 years of age presenting treatment-resistant depression. Full details are available on the Psychopharmacology in Maastricht website. Several researchers from Maastricht University will be presenting their latest findings during ICPR 2020, focusing on placebo-controlled studies on LSD microdosing, ayahuasca and psilocybin. To see the full programme and secure your spot at this year’s conference, visit: https://icpr2020.net/